Genetic tests rise, staff struggle

Health system’s ability to cope tested

Genetic tests are being performed in such big numbers that there is a risk they will overwhelm the ability of doctors to keep up and swamp funding arrangements.

That is the view of specialists after a survey revealed the extent of DNA testing in Australia.

A total of 160,000 tests – for more than 400 medical conditions – were performed in 2006, according to the first national audit of the burgeoning field.

“We’re in transition from a cottage industry to the inclusion of genetic testing in mainstream medicine,” said Dr Graeme Suthers, who conducted the study funded by the federal Department of Health and Ageing.

About 40 per cent of the tests involved screening healthy people for genes that could cause diseases such as cystic fibrosis in their children, or screening donor tissue for compatibility in transplants or transfusions.

Twenty eight per cent were to diagnose or eliminate a genetic cause for unexplained symptoms, and 8 per cent were conducted on cancer cells to check for genetic damage. Tests on family members of people with cancer-causing gene mutations accounted for 5 per cent.

Chromosome tests on unborn children and DNA testing of microbes to identify infections were not surveyed; nor were non-medical uses like paternity tests.

Gene analysis of cancers was rising, said Dr Suthers, the head of the familial cancer unit at the South Australian Clinical Genetics Service, as evidence showed some drugs were more effective against tumours with particular genetic characteristics.

“In women with breast cancer there’s a good case for a genetic profile,” said Dr Suthers, who will present the results in Adelaide today.

Bev Rowbotham, the president of the Royal College of Pathologists of Australasia, said the survey results made a strong case to address funding for gene tests. Few tests received Medicare funding, Dr Rowbotham said, meaning patients were obliged to seek tests through overstretched genetics clinics at public hospitals, or pay for private tests.

Federal and state governments needed to find new ways to assess gene tests to determine quickly which should receive public funding, she said.

The clinical associate professor, Kristine Barlow-Stewart, also the director of the centre for genetics education at the Royal North Shore Hospital, said doctors needed more genetics training to help them decide when to order gene tests and to reassure patients that a gene mutation was usually only one factor in developing disease.

“[Doctors] talk in numbers and percentages but generally people think in black and white: I will get [a disease] or I won’t get it,” she said.

from a Sydney Morning Herald article – August 6, 2008 by Julie Robotham, Medical Editor, Sydney Morning Herald

Wheelies tow air freighter

Set Guinness World Record

In early September a team of wheel chaired folks in England set a world record by pulling an airplane for the British Disabled Flying Association charity.

And not just a small one – they towed a 65 tonne Boeing 757 freighter for over 100 metres!

Watch the amazing YouTube clip – it is truly inspirational!

Metabolic cause of some spastic paraplegia

Although poorly recognised by neurologists, spastic paraparesis can be one of the results of some metabolism disorders in children and adults

These metabolic causes are often treatable, making it essential that metabolic causes for spastic paraparesis are considered as part of the diagnostic process.

Spastic paraparesis is a general term describing progressive stiffness and weakness in the lower limbs caused by pyramidal tract lesions. This clinical situation is frequently encountered in adult neurology. The diagnostic survey is usually limited to searching for acquired causes (spinal cord compression, inflammatory, metabolic, infectious diseases) and the so-called ‘hereditary spastic paraparesis’.

Although poorly recognized by neurologists, spastic paraparesis is also one of the multiple presentations of inborn errors of metabolism (IEMs) in children and adults. Pyramidal signs are usually included in a diffuse neurological or systemic clinical picture; however, in some cases spastic paraparesis remains the only symptom for years.

Since these metabolic causes are often treatable, it is essential to include them in the general diagnostic approach to spastic paraparesis. Here we review IEMs causing paraparesis in adults.

SOURCE: J Inherit Metab Dis. 2007 Nov;30(6):855-64.

Hereditary spastic paraparesis in adults associated with inborn errors of metabolism: a diagnostic approach.

Sedel F, Fontaine B, Saudubray JM, Lyon-Caen O.

Federation of Nervous System Diseases, The Salpêtrière Hospital, Pierre et Marie Curie University, Paris, France. frederic.sedel@psl.aphp.fr

Genetic Testing – some new considerations

The distinction between hereditary spastic paraplegias and other entities, such as cerebellar ataxias or leucodystrophies is blurred

Genetic testing is progressively more complex and clinical and other information concerning the phenotype is now crucial for choosing an appropriate genetic testing procedure for each patient.

Hereditary spastic paraplegias are a genetically heterogeneous group of diseases. Recent advances concerning their nosology and molecular bases have greatly improved the genetic diagnosis of these diseases, with implications for genetic counselling.

The recent identification of new genes and loci, however, has blurred the distinction between hereditary spastic paraplegias and other entities, such as cerebellar ataxias or leucodystrophies. Cerebral MRI and the familial history of each patient with spastic paraplegia are the minimal clinical elements needed to orient genetic testing.

For SPG4, the gene most frequently involved in hereditary spastic paraplegias, a novel mutational mechanism was described, which allows detection of an increased number of cases. In autosomal recessive forms, mutations in the recently identified SPG11 gene seem to account for a majority of the complex forms of the disease with atrophy of the corpus callosum. In addition, the SACS gene has been implicated in an increasing number of cases of various origins.

SOURCE: Curr Opin Neurol. 2007 Dec;20(6):674-80.

Hereditary spastic paraplegias: an update.

Depienne C, Stevanin G, Brice A, Durr A.

INSERM, U679, Paris, France.

Botox not just for wrinkles

17 of 19 patients in the study had measurably reduced spasticity after receiving botox injections. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect.

Hereditary spastic paraplegia (HSP) is characterized by lower extremity spasticity. Symptomatic therapy generally includes physical therapy and oral antispastic agents, in selected cases intrathecal baclofen. Because of the positive results in other treatments of spasticity, the use of botulinum neurotoxin type A (BoNT-A) might also be considered for patients with HSP.

We report the effect of BoNT-A injections in 19 unselected patients with HSP treated by the members of the German Spasticity Education Group. In 17 patients, the modified Ashworth scale had improved by one point. In one patient, it improved by three points. Most of the patients reported reduction of spasticity. BoNT-A injections were continued in 11 of 19 patients (57.9%). All of the patients with continued injections had a good or very good global subjective improvement. Patients with less pronounced spasticity and patients with accompanying physical therapy tended to exhibit a better effect. Only four patients reported adverse effects which were increased weakness in three patients and pain in one patient. BoNT-A injections appear to reduce spasticity effectively and safely, especially in patients with mild to moderate spasticity. The preliminary results of our case series should encourage larger studies of BoNT-A injections in HSP.

2007 Movement Disorder Society
SOURCE: Mov Disord. 2008 Jan 30;23(2):228-33.
Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia–report of 19 cases.
Hecht MJ, Stolze H, Auf dem Brinke M, Giess R, Treig T, Winterholler M, Wissel J; German Spasticity Education Group.
Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany. martin.hecht@bkh-kaufbeuren.de

Scooter does the trick!

A woman HSPer from Norway uses an adult-sized, (stand on top, unmotorized) foldable, kick scooter like the shiny silver metal Blades so popular with kids. She walks badly without it but with it is quick and cool and yes – even graceful!

She has been using it for years and believes that she has learned and improved her balance with it and gets around very quickly. Also nice, this equipment is relatively cheap and easily transportable.

Find a Physio

Benefits of Exercise

Many with HSP benefit from a well designed program of stretching, strengthening and exercise for improved cardiovascular fitness, mobility and flexibility, and spasticity reduction.

If you have not already been to a physio, there may be significant benefits from doing so.  Here’s how to find one:

The Australian Physiotherapy Association website has a ‘Find a Physio’ tool.  The search function allows you to sort by Location and Clinical Area –  choose ‘Neurology’, as a physiotherapist with a neurology interest is likely to be a good resource in developing a program for an HSPer.

Gene Testing- Questions and Answers

GENE TESTING
QUESTIONS and ANSWERS
What is a gene and what is a mutation?
A gene is a small region that can be located on the DNA. Genes are units of inheritance. Each contains a coding sequence that determines the protein the gene produces.
An error in the coding sequence of a particular gene results in the gene producing the wrong protein and the error is called a mutation.. HSP genes have been identified and gene tests are used to identify the mutation.
What’s new for people with HSP and those at risk?
Gene tests are now available in Australia for the first time.
At the initiation of and funding by HSPRF, the Northcott Neuroscience Lab of ANZAC Research Institute has developed gene tests for three major HSP genes (SPG4, SPG3A and SPG6). Mutations in one of these three genes cause about half the incidence of HSP. In total there are 11 genes for which diagnostic tests are available world wide out of 31 HSP genes that have been located.
What kinds of tests are there?
There are 2 types of tests-the first is about discovering the causal mutation and the second is about screening for the presence or absence of the discovered mutation.
**Tests for discovery/detection of a mutation
This is the first step in determining the cause of the disorder in a family. It is conducted via a blood sample of a single family representative with the disease. The test will detect the mutation and establish the aberrant coding sequence and type of mutation.
The clinical geneticist or neurologist will consider the patients’ condition and nominate the gene for which a test is to be  conducted based on the type of HSP the patient appears to have, family history and their knowledge of the prevalence of each gene  (SPG4 is the most prevalent—30% to 40% of all HSP).
If the gene test is found to be negative, (no mutation can be found), the doctor and patient will consider the diagnostic issue again and may nominate the next most likely gene and so on until the mutation is found. Often families share in meeting the costs of mutation detection because the information is of benefit to all sections of the family.
If the mutation is still not found from these tests, arrangements can be made via the testing laboratory for the sample to be sent to a research laboratory overseas that seeks mutations in rarer genes and. This additional testing would be of no cost to the patient but the test would have to be repeated in a recognized testing laboratory for it to become clinically recognized and a cost would be incurred at this time.
**Predictive testing / pre-symptomatic genetic testing/screening
This is the diagnosis for the rest of the family when a family gene has been detected (see above). It is a more routine test and costs much less than the detection test.
With the knowledge of the family mutation, family members who are showing no physical signs of HSP can have their DNA screened for the presence or absence of the family mutation. As onset can be any time from childhood to 70years, many will want to know what their future may hold. This test can prove the absence of an HSP gene mutation in individual members of a family and will remove younger peoples’ concern about having children. It is always conducted in association with genetic counselling to help deal with the ramifications of both good news and not so good news. This test requires a consent form signed by the patient, 2 separate blood samples taken on separate occasions and genetic counseling involvement.
My neurologist has already told me I have HSP. Why do I need more tests?
You would have had tests in the neurologist’s clinic (reflex, scans etc) that indicate you have HSP. The term HSP is representative of a number of conditions caused by a mutation in one of 30 different genes. Hence you have been advised of the disease group affecting you but not the gene.
The gene test is carried out to:-
  • confirm the clinical test- some forms of MS present just like HSP in early stages. Any doubts you may have some other ‘brain / legs disconnect’ disease is eliminated.
  • determine the cause- the gene with the fault and the type of mutation
  • benefit relatives at risk by establishing the basis for existing and future family members who will then be able to screen for the presence or absence of the family mutation.
When I know my mutation how is it going to help me?
You have this knowledge but it is also available (with your consent) to other family members who can consider, with the genetic counselor, whether to screen for the presence or absence of the mutation (undertake predictive testing).
They can screen and, if they test positive, they can make more informed life choices including preventing their offspring inheriting the mutation, preparing for the likelihood of onset with physiotherapy, housing and health insurance choices and many others.
If they test negative they have eliminated what may have been a deep seated worry for them selves and their current and future children and their children.
You can see that your decision can have much wider ramifications than just your medical case ie. present and, as yet, unborn relatives at risk.
How do I get started?
Clinical genetics services are listed on the Centre for Genetics website and can be found, with phone numbers and addresses, at www.genetics.com.au/services/counsel.html . If you are not on the internet, phone your local public hospital and, if they do not have a genetics service (some call it genetics counseling service) they will tell you the closest hospital that does.
How can my partner and I prevent our children inheriting HSP?
This is a subject that you and your partner should discuss with a genetic counsellor. However the essentials are set out below.
If the family mutation is not known then the partner concerned should undergo the mutation detection/ discovery test.
If the family mutation is known and the partner has not been tested for the presence or absence of the family mutation then that should become the first step. A negative result is good news.
Once a mutation is known the couple should have discussions with a genetic counselor on the options. There are three options:-
** 1 Pre-natal testing
A pre-requisite is the evidence of one parent with an HSP mutation that has been detected, referral from an appropriate doctor and a consent form signed by the mother-to-be undertaking the test. Genetic counseling applies.
Pre-natal testing involves taking a sample of the placenta at 11or12 weeks’ gestation, for DNA extraction and testing for the presence or absence of the known mutation
If the test result is positive (mutation is present) then the couple would make the decision whether to terminate or not with genetic counseling and medical advice.
** 2 Pre-implantation genetic diagnosis (PGD)
This method provides for only mutation free embryos being implanted to the womb of the mother to be.
A pre-requisite is evidence of one parent with an HSP mutation that has been described, referral of an appropriate doctor and a consent form signed by both parents. Genetic counseling applies.
PGD involves an IVF clinic and assisted reproduction technology including stimulation of ovaries to enable the collection of a number of eggs which are fertilized in the laboratory with prospective male parent’s sperm. The IVF Clinic takes an embryo biopsy of 4 to 6 cells on day 5 after fertilization. Then gene tests are performed on each cell to identify embryos without the mutation present and which can be used for implantation.
For some families at risk of passing on a genetic disorder to their children, PGD offers a more acceptable alternative to starting a pregnancy and later terminating.
For couples with a moral or religious objection to pregnancy termination and who also are at risk of having a child with the genetic condition, this technique may provide the opportunity to have an unaffected child.
** 3 Proceed with neither of the above interventions
Relevant Gene Testing News
*Some actual positives have tested negative
During 2006 European scientific team discovered that about 15% of tests for mutations in SPG4 tested negative when they were actually positive. A particular type of mutation (duplication/deletion) was being missed in conventional testing methods.
ANZAC Research Institute became aware of the findings before they were published. The German scientist leading the team assisted ANZAC R I in establishing the process for duplication/deletion testing to ensure this type of mutation is not missed. The weakness does not occur in the new Australian tests.
An Australian HSPer, who tested negative to SPG4 in a conventional overseas tests in 2004, actually tested positive from a sample contributed to the ANZAC R I research programme in 2006.
*Therapy may not be too far away- for some
A new drug that is in Phase 2 (for efficacy and safety in humans) trials for Cystic Fibrosis and Duchene Muscular Dystrophy is being watched by HSP groups around the world. This drug (PTC124) works only on a particular type of mutation (‘non-sense’ mutations) and, while the research focus has been on those two diseases, the manufacturers see it as likely to have much wider application.
The drug blocks the mutation’s message in the DNA to stop the production of a protein that is needed. The drug is unusual in that it targets non-sense mutations regardless of the gene and disease involved.
The new gene tests will record the type of mutation found and each person tested will know whether or not they have a non-sense mutation.
*The new HSP gene testing service is due to commence in Nov.

HSP & other rare diseases

All HSPers know they have a rare disease but may not know it is one of 6,000 known by the US National Institutes of Health (NIH) Office of Rare Diseases (ORD).  ORD defines a rare disease (often called ‘orphan disease’) as one with fewer than 200,000 people being affected in the USA.  Another definition is – a disease that affects fewer than 5 people in 10,000. Other estimates suggest that between 6% and 10% of the community suffer from a rare disease.

ORD issue research grants and facilitate partnering of patient support groups with the National Institutes of Health on research programmes.  They generally play a coordinating role with activities associated with rare diseases. Their website is: www.rarediseases.info.nih.gov/
  
The US National Organization for Rare Disorders (NORD) is supported by ORD but runs independently as a non-government charity.  It’s website is: http://www.rarediseases.org/

It has 2,000 patient organizations on its membership and lists 1,160 disorders.  Our disorder is shown as “paraplegia, hereditary spastic” and is number 398 on the list.  The majority of rare diseases are genetic disorders.

The EU has a similar organization to NORD and its website is www.eurordis.org.  Canada and NZ both have patient-representative groups for rare diseases ( www.cord.ca/ and www.nzord.org.nz/ )

The original purpose of these support organizations was to gain access to drugs that were effective on the rare disease but lacked regulatory approval and were not seen by pharmaceutical companies to be a commercially viable proposition to develop for one or more rare diseases.  Hence the term “orphan drugs”. The US has initiated incentives to encourage pharmaceutical companies to invest in more research and development for rare diseases.

While there are no similar rare disease organizations in Australia, the Government commenced an Orphan Drug Programme in 1998 which was modeled on the US programme.  Support for the appropriate drug availability has been provided by forgoing some application fees and streamlining the process including the recognition of FDA approvals. There is still no coordinated approach from Governments or patient groups involved with rare diseases in Australia.

Baclofen Pump Teleconference

Baclofen Pump Teleconference

from Medtronic, the makers of the Baclofen Pump . . . .

If you or someone you care for has tight, stiff muscles related to  stroke, multiple sclerosis, cerebral palsy, spinal cord injury, or brain injury you know that this condition (called severe spasticity) can make movement difficult or uncontrollable. It can make doing even the smallest things exhausting or impossible.

Did you know that there is a therapy available that may help provide better movement and control?

You are invited to learn about Medtronic ITB TherapySM (Intrathecal Baclofen Therapy) by participating in an educational teleconference during which a doctor will talk about severe spasticity, explain how the therapy works, and discuss recent research on the treatment.

A teleconference allows you to listen to and speak with a physician and others living with spasticity on the phone, from the comfort of your home. Once you register, you will receive a toll-free number to call to participate in the teleconference.  Note to non US residents – this call will be charged at international rates to the US by your provider.

http://www.movementforliving.com
Family and friends are welcome to listen in.

The teleconferences will be held on:

2007 Dates:

August 14
October 9 (Pediatric Focus)
November 13

2008 Dates:

January 8
February 12
March 11
April 8 (Pediatric  Focus)

The teleconferences will be held at 7 p.m. Eastern time (USA) which is 11 a.m. EST (+ 1 day) in Australia.

To register, visit www.MovementforLiving.com or call toll free 1-888-743-8348.  From Australia, this is not a free call and the number to dial is 0011 1 888 743 8348.

To make sure the information you request from this event goes straight to your email inbox, please add itbtherapy@medtroniceducation.com to your address book. Thank you!

We hope you find this information valuable. However, if you wish to be removed from Medtronic’s severe spasticity mailing list, please click here <https://www.medtroniceducation.com/kma/www/itb_optout/optout.jsp?Lead.LeadID=107e961fff700wrobleski>  or send a request in writing to Medtronic 710 Medtronic Parkway – LN275 Minneapolis, MN 55432 USA

 Your privacy is important to us. To read our privacy policy, visit: www.medtronic.com/statements/privacy.html <http://www.medtronic.com/statements/privacy.html> .
 
 Important Safety Information <http://www.medtronic.com/servlet/ContentServer?pagename=Medtronic/Website/SafetyCategory&amp;ConditionName=Severe+Spasticity>

Lioresal® is a registered trademark of Novartis Pharmaceuticals Corporation.